Even on a day when there finally was good news about Emergent BioSolutions’ heavily scrutinized manufacturing facility in Baltimore—as it has been cleared to produce COVID-19 vaccines—there also was another dose of bad news involving the plant.
According to a report from Reuters based on inspection records and accounts from regulators, millions of doses of the AstraZeneca COVID-19 vaccine that were produced by Emergent in Baltimore, were supplied to Mexico and Canada before U.S. inspectors had certified the facility.